Although NSAIDs are associated with risk reduction in breast cancer, the relationship is not a gradient-dose response.
Although non-steroidal anti-inflammatory drugs (NSAIDs) are associated with risk reduction in breast cancer, the relationship is not a gradient-dose response where increasing dose confers a protective effect, researchers report in the Oct. 15 issue of the Journal of the National Cancer Institute.
Bahi Takkouche, MD, PhD, of the University of Santiago de Compostela in Spain, and colleagues performed a meta-analysis of data from 38 studies, involving 2,788,715 women, to examine the association between NSAIDs and breast cancer.
Overall, NSAIDs reduced the risk by 12%, when compared to non-users, the researchers found. Aspirin and ibuprofen reduced the threat by 13% and 21%, respectively. Increased intake, either increased total dose or longer duration, did not alter the risk reduction among NSAIDs, aspirin, or ibuprofen, the authors report.
Takkouche B, Regueira-Méndez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst. 2008;100:1439-1447. doi:10.1093/jnci/djn324.
Study: Plant-based diets lower hypertensive disorders of pregnancy risk
March 28th 2024A recent study suggests that adherence to plant-based diets significantly decreases the risk of developing hypertensive disorders of pregnancy, shedding light on dietary interventions for maternal health.
Read More
How genetic variables impact oral contraceptive use and VTE risk
March 27th 2024A comprehensive study delved into the interplay of polygenic and hereditary factors in venous thromboembolism risk among oral contraceptive users, shedding light on potential genetic markers for refined risk assessment and counseling.
Read More